
Myles Minter
Stock Analyst at William Blair
(4.93)
# 191
Out of 5,134 analysts
616
Total ratings
54%
Success rate
26.3%
Average return
Main Sectors:
Stocks Rated by Myles Minter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Downgraded: Hold | n/a | $223.37 | - | 31 | Oct 27, 2026 | |
| VOR Vor Biopharma | Initiated Coverage: Buy | n/a | $19.42 | - | 1 | Oct 21, 2026 | |
| SLN Silence Therapeutics | Downgraded: Hold | n/a | $19.83 | - | 28 | Oct 19, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | n/a | $78.30 | - | 12 | Oct 6, 2026 | |
| ANRO Alto Neuroscience | Reiterated: Buy | n/a | $29.54 | - | 15 | Oct 2, 2026 | |
| CTNM Contineum Therapeutics | Reiterated: Buy | n/a | $9.86 | - | 12 | Sep 30, 2026 | |
| CAMP Camp4 Therapeutics | Reiterated: Buy | n/a | $3.80 | - | 13 | Sep 29, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | n/a | $8.36 | - | 23 | Sep 24, 2026 | |
| RAPP Rapport Therapeutics | Reiterated: Buy | n/a | $26.15 | - | 4 | Sep 23, 2026 | |
| VTGN Vistagen Therapeutics | Reiterated: Hold | n/a | $0.1805 | - | 14 | Sep 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $29.06 | - | 55 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $538.60 | - | 35 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $91.81 | - | 22 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $40.48 | - | 16 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.52 | - | 15 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.82 | - | 14 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.4289 | - | 16 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.54 | - | 11 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $141.69 | - | 64 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.54 | - | 12 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $18.74 | - | 14 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.61 | - | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.70 | - | 18 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.02 | - | 20 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.09 | - | 13 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $167.40 | - | 32 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $165.04 | - | 17 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $253.40 | - | 31 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $960.04 | - | 19 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $17.97 | - | 1 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.63 | n/a | 3 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.55 | n/a | 3 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $328.13 | n/a | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.30 | n/a | 15 | Dec 29, 2022 |
Moderna
Oct 27, 2026
Downgraded: Hold
Price Target: n/a
Current: $223.37
Upside: -
Vor Biopharma
Oct 21, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $19.42
Upside: -
Silence Therapeutics
Oct 19, 2026
Downgraded: Hold
Price Target: n/a
Current: $19.83
Upside: -
BridgeBio Pharma
Oct 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $78.30
Upside: -
Alto Neuroscience
Oct 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $29.54
Upside: -
Contineum Therapeutics
Sep 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.86
Upside: -
Camp4 Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.80
Upside: -
Arcturus Therapeutics Holdings
Sep 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $8.36
Upside: -
Rapport Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $26.15
Upside: -
Vistagen Therapeutics
Sep 23, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.1805
Upside: -
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $29.06
Upside: -
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $538.60
Upside: -
Sep 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $91.81
Upside: -
Sep 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $40.48
Upside: -
Sep 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.52
Upside: -
Sep 9, 2026
Rated: Hold
Price Target: n/a
Current: $13.82
Upside: -
Aug 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.4289
Upside: -
Aug 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.54
Upside: -
Aug 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $141.69
Upside: -
Aug 7, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.54
Upside: -
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $18.74
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.61
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.70
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.02
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.09
Upside: -
Jul 31, 2026
Reiterated: Buy
Price Target: n/a
Current: $167.40
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $165.04
Upside: -
Jul 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $253.40
Upside: -
Jun 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $960.04
Upside: -
Mar 31, 2026
Reiterated: Buy
Price Target: n/a
Current: $17.97
Upside: -
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $2.63
Upside: n/a
Sep 28, 2023
Reiterated: Buy
Price Target: n/a
Current: $2.55
Upside: n/a
Mar 3, 2023
Downgraded: Hold
Price Target: n/a
Current: $328.13
Upside: n/a
Dec 29, 2022
Rated: Hold
Price Target: n/a
Current: $2.30
Upside: n/a